1. Department of Physiology and Pharmacology, University of Western Ontario, London, ON, Canada;
2. Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA;
3. Division of Pre-Clinical Innovation, Therapeutic Development Branch, National Center for Advancing Translational Sciences, Bethesda, MD, USA;
4. Novartis Institutes for BioMedical Research, Cambridge, MA, USA;
5. Program in Biophysics, University of Michigan, Ann Arbor, MI, USA;
6. Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA;
7. Nicholas School of the Environment, Duke University, Durham, NC, USA;
8. Aranmore Pharma Consulting, Lawrenceville, NJ, USA;
9. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden;
10. Relay Therapeutics, Cambridge, MA, USA;
11. Gilead Alberta ULC, Edmonton, AB, Canada;
12. College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA;
13. Department of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, MI, USA;
14. Optibrium Limited, Cambridge, UK;
15. Denali Therapeutics, South San Francisco, CA, USA;
16. Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA;
17. Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, CA, USA